Clinical trials: in Uruguay
Neoplasms, Bereavement
ERANet-LAC CODE: International Care Of the Dying Evaluation
Providing high quality care for dying patients and their families is very important. One way one can assess the care provided is to ask bereaved relatives to complete a questionnaire after their family member has died.
- Conditions
- Neoplasms, Bereavement, Quality of Life
- Trial name
- NCT03566732
- Where
- 20 sites in Argentina, Brazil and 5 more
- Volunteers
- 914 people
- Sponsor
- University of Bergen
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Sinus Node Dysfunction
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
- Trial name
- IMPROVE Brady (NCT01643707)
- Testing
- Evidence based guidelines and tools
- Where
- 21 sites in Argentina, Bangladesh and 5 more
- Volunteers
- 1,342 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Von Willebrand Disease
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
This is an observational study, hence there is no study hypothesis
- Trial name
- NCT01602419
- Testing
- Patients using Wilate as standard of care
- Where
- 24 sites in United States, Argentina and 8 more
- Volunteers
- 120 people
- Sponsor
- Octapharma
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Acute Respiratory Failure
Third International Study on Mechanical Ventilation
The objective of this study is to obtain a better understanding of the spectrum of use of mechanical ventilation in intensive care units: 1.
- Trial name
- ISMV (NCT01093482)
- Where
- 477 sites in United States, Argentina and 36 more
- Volunteers
- 8,151 people
- Sponsor
- Hospital Universitario Getafe
Breast Cancer
An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
This is a descriptive, prospective, observational and epidemiological study on participants recently diagnosed with breast cancer to evaluate the HER2 status by IHC and SISH procedures.
- Trial name
- NCT02535026
- Where
- 4 sites in Peru, Uruguay
- Volunteers
- 580 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Primary objective: Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin…
- Trial name
- NCT00021255
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 42 sites in United States, Argentina and 40 more
- Volunteers
- 3,222 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents.
- Trial name
- NCT00502996
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 49 sites in Argentina, Brazil and 8 more
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either.
- Trial name
- NCT00949910
- Testing
- Erlotinib
- Where
- 543 sites in Albania, Argentina and 49 more
- Volunteers
- 6,586 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
This open-label, non-comparative, multi-center study will assess the safety profile and efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in participants with epithelial ovarian cancer, fallopian…
- Trial name
- NCT01239732
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 242 sites in Argentina, Austria and 35 more
- Volunteers
- 1,021 people
- Sponsor
- Hoffmann-La Roche
Anemia
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
This single arm study will assess the efficacy and safety of Mircera when administered once monthly, subcutaneously or intravenously, for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia.
- Trial name
- NCT00517413
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 28 sites in Argentina, Brazil and 7 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy.
- Trial name
- NCT01543503
- Where
- 154 sites in Argentina, Belgium and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior…
- Trial name
- NCT00391092
- Testing
- bevacizumab [Avastin], Docetaxel, Herceptin
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active…
- Trial name
- NCT00754572
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 69 sites in Argentina, Brazil and 8 more
- Volunteers
- 418 people
- Sponsor
- Hoffmann-La Roche
Respiratory Syncytial Virus Infection
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
The study was designed to gather information regarding the use of palivizumab for the prophylaxis for respiratory syncytial virus (RSV) infection in high-risk infants in selected countries within Latin America.
- Trial name
- NCT01297504
- Where
- 24 sites in Argentina, Chile and 5 more
- Volunteers
- 464 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Elevated High-sensitivity C-Reactive Protein (hsCRP)
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of…
- Trial name
- NCT00239681
- Testing
- Rosuvastatin
- Where
- 856 sites in United States, Argentina and 25 more
- Volunteers
- 17,802 people
- Sponsor
- AstraZeneca
Breast Cancer
Docetaxel in Breast Cancer
Primary objective : To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer…
- Trial name
- NCT00312208
- Testing
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,299 people
- Sponsor
- Sanofi